written on 18.03.2014

New incontinence data could give Ipsen's Dysport a path to lucrative urology use


Ipsen announced &quot;positive results&quot; in a Phase II trial of <span style="font-size: 13px;">Dysport in patients with urinary incontinence. That could put Ipsen&#39;s drug in line for more head-to-head competition with Allergan&#39;s Botox, which has successfully expanded into several medical uses.</span>